TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Rating of “Hold” from Analysts

TScan Therapeutics, Inc. (NASDAQ:TCRX) has received an average recommendation of “Hold” from the six brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $6.00.

Several brokerages have recently commented on TCRX. Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a report on Tuesday, April 21st. Wedbush upped their price objective on shares of TScan Therapeutics from $4.00 to $5.00 and gave the stock an “outperform” rating in a report on Thursday, March 5th. Finally, Wall Street Zen lowered shares of TScan Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th.

Hedge Funds Weigh In On TScan Therapeutics

Large investors have recently made changes to their positions in the stock. Aberdeen Group plc increased its stake in TScan Therapeutics by 52.0% during the 3rd quarter. Aberdeen Group plc now owns 1,354,820 shares of the company’s stock worth $2,466,000 after buying an additional 463,372 shares during the period. Renaissance Technologies LLC increased its stake in TScan Therapeutics by 37.5% during the 4th quarter. Renaissance Technologies LLC now owns 1,141,069 shares of the company’s stock worth $1,141,000 after buying an additional 311,150 shares during the period. Jane Street Group LLC increased its stake in TScan Therapeutics by 377.5% during the 4th quarter. Jane Street Group LLC now owns 388,284 shares of the company’s stock worth $388,000 after buying an additional 306,968 shares during the period. Marshall Wace LLP increased its stake in TScan Therapeutics by 627.5% during the 4th quarter. Marshall Wace LLP now owns 339,240 shares of the company’s stock worth $339,000 after buying an additional 292,610 shares during the period. Finally, XTX Topco Ltd increased its stake in TScan Therapeutics by 1,142.5% during the 4th quarter. XTX Topco Ltd now owns 219,001 shares of the company’s stock worth $219,000 after buying an additional 201,375 shares during the period. 82.83% of the stock is currently owned by institutional investors and hedge funds.

TScan Therapeutics Stock Performance

NASDAQ:TCRX opened at $1.08 on Friday. The company has a debt-to-equity ratio of 0.34, a current ratio of 6.65 and a quick ratio of 6.65. The firm has a market capitalization of $70.58 million, a price-to-earnings ratio of -1.12 and a beta of 1.06. The company’s 50-day moving average is $1.10 and its two-hundred day moving average is $1.07. TScan Therapeutics has a 1-year low of $0.88 and a 1-year high of $2.57.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, meeting the consensus estimate of ($0.22). TScan Therapeutics had a negative net margin of 1,360.61% and a negative return on equity of 91.94%. The company had revenue of $0.98 million for the quarter, compared to analyst estimates of $2.50 million. Analysts forecast that TScan Therapeutics will post -1.11 EPS for the current year.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.